New clinical study to help people with spinal cord injury

Repeated infections and subsequent antibiotic treatments are a painful part of daily life for patients with spinal cord injury, who use urinary catheters. Bactiguard and the Centre for Spinal Cord Injury are now starting a new clinical trial, which aims to increase the quality of life for these patients. 

“We are excited about the study and the possibility to improve the quality of life for these patients. Spinal cord injured patients are often at great risk of constantly being affected by painful urinary tract infections, which can be very limiting”, says Lena Lindbo, urotherapist and COO at the Centre for Spinal Cord Injury and Professor Åke Seiger, physician and R&D Manager at the Rehab Station Stockholm.

Many spinal cord injured patients have difficulties in emptying their bladder in a natural way and therefore use indwelling suprapubic urinary catheters. A large number of these patients suffer from recurrent urinary tract infections, requiring antibiotic treatment, which has a negative impact on their quality of life. In order to reduce the number of infections for these patients, Bactiguard is starting a clinical study together with the Centre for Spinal Cord Injury, Sweden’s leading clinic for spinal cord injured patients, at the Rehab Station Stockholm.

“We want to make a difference to these patients and reduce the suffering a urinary tract infection involves. In individual patient cases, within this patientgroup, it has already been documented that Bactiguard’s infection prevention catheters significantly reduce the risk of acquiring a urinary tract infection. We now hope to verify this further in a more comprehensive, high-quality study”, says Dorota Johansson, Director of R&D and Clinical Trials at Bactiguard.

The purpose of the study is to evaluate the effect of Bactiguard Infection Protection urinary catheters (BIP Foley Catheters) in the reduction of catheter-associated urinary tract infections and the need for antibiotic treatment for spinal cord injured patients with suprapubic indwelling catheters. The patients involved in this study are so-called high-risk patients, with at least three urinary tract infections during the past year. The outcome of the study will be based on a comparison of approximately six months use of a Bactiguard coated Foley catheter and approximately six months use of a standard catheter for each patient in the study.

For further information, please contact:
Ulrika Berglund, Head of External Affairs, Cell & Text: +46 708 800 407

About Bactiguard
Bactiguard is a Swedish medtech company with a global presence, offering a solution that prevents healthcare associated infections caused by medical devices. By preventing infections, we contribute to a reduced use of antibiotics and the spread of multi-resistant bacteria, which is a growing problem worldwide. We save lives, increase patient safety and significantly reduce the cost for the healthcare and society. Our technology is well-proven, safe and tissue friendly and consist of a thin layer of noble metals that prevents bacterial growth. The coating can be applied on almost all medical devices. Bactiguard-coated urinary catheters are market leading in the US and Japan and the company has also its own product portfolio consisting of Foley catheters, central venous catheters and endotracheal tubes. Bactiguard is a growth company, focused on markets in Europe, Middle East, Asia and Latin America. The company has about 70 employees worldwide, mainly at the headquarters in Stockholm and the production facility in Malaysia and is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com

Tags:

About Us

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with Bactiguard's coating are market leaders in the USA and Japan through our licensing partner BD. Bactiguard's product portfolio also includes Hydrocyn® aqua, a non-alcoholic product line for wound care and disinfection. Hydrocyn effectively kills viruses, bacteria and fungi while being biocompatible, pH neutral and tissue friendly. The active ingredient hypochlorous acid is the same substance as the body's immune cells use in their defence against infectious organisms. Bactiguard is in a strong expansion phase in the markets in Europe, China, India and the Middle East through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about Bactiguard www.bactiguard.com

Subscribe

Media

Media

Quick facts

Repeated infections and subsequent antibiotic treatments are a painful part of daily life for patients with spinal cord injury, who often use Foley catheters. Bactiguard and the Centre for Spinal Cord Injury are now starting a new clinical trial, which aims to increase the quality of life for these patients.
Tweet this

Quotes

We are excited about the study and the possibility to improve the quality of life for these patients.
Lena Lindbo, urotherapist and COO at the Centre for Spinal Cord Injury and Professor Åke Seiger, physician and R&D Manager at the Rehab Station Stockholm.
We want to make a difference to these patients and reduce the suffering a urinary tract infection involves.
Dorota Johansson, Director of R&D and Clinical Trials at Bactiguard.